Lotus Pharmaceutical Co., Ltd. (1795.TW)
TWD 260.5
(-1.14%)
TWD 260.5
(-1.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 9.51 Billion TWD | 10.14% |
| 2022 | 8.64 Billion TWD | 83.49% |
| 2021 | 4.71 Billion TWD | -6.24% |
| 2020 | 5.02 Billion TWD | 30.88% |
| 2019 | 3.83 Billion TWD | 162.65% |
| 2018 | 1.46 Billion TWD | -66.87% |
| 2017 | 4.41 Billion TWD | 62.56% |
| 2016 | 2.71 Billion TWD | -34.0% |
| 2015 | 4.11 Billion TWD | 14.2% |
| 2014 | 3.6 Billion TWD | 911.62% |
| 2013 | 355.92 Million TWD | 620.27% |
| 2012 | 49.41 Million TWD | 0.0% |
| 2011 | - TWD | -100.0% |
| 2010 | 307.29 Million TWD | 3411.9% |
| 2009 | 8.75 Million TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 7.97 Billion TWD | -15.26% |
| 2024 Q1 | 9.63 Billion TWD | -1.11% |
| 2023 Q2 | 8.09 Billion TWD | -16.87% |
| 2023 FY | 9.51 Billion TWD | 10.14% |
| 2023 Q1 | 9.74 Billion TWD | 12.71% |
| 2023 Q3 | 8.56 Billion TWD | 5.74% |
| 2023 Q4 | 9.51 Billion TWD | 11.17% |
| 2022 Q4 | 8.64 Billion TWD | 23.68% |
| 2022 Q3 | 6.98 Billion TWD | 112.08% |
| 2022 Q2 | 3.29 Billion TWD | -27.58% |
| 2022 FY | 8.64 Billion TWD | 83.49% |
| 2022 Q1 | 4.55 Billion TWD | -3.41% |
| 2021 Q3 | 4.92 Billion TWD | -20.34% |
| 2021 Q1 | 6.44 Billion TWD | 28.35% |
| 2021 FY | 4.71 Billion TWD | -6.24% |
| 2021 Q2 | 6.18 Billion TWD | -4.1% |
| 2021 Q4 | 4.71 Billion TWD | -4.38% |
| 2020 Q2 | 5.22 Billion TWD | 47.35% |
| 2020 Q1 | 3.54 Billion TWD | -7.61% |
| 2020 FY | 5.02 Billion TWD | 30.88% |
| 2020 Q4 | 5.02 Billion TWD | -1.03% |
| 2020 Q3 | 5.07 Billion TWD | -2.86% |
| 2019 FY | 3.83 Billion TWD | 162.65% |
| 2019 Q4 | 3.83 Billion TWD | -7.78% |
| 2019 Q3 | 4.16 Billion TWD | 31.3% |
| 2019 Q1 | 3.13 Billion TWD | 114.31% |
| 2019 Q2 | 3.17 Billion TWD | 1.21% |
| 2018 Q2 | 2.25 Billion TWD | -45.78% |
| 2018 Q3 | 1.97 Billion TWD | -12.41% |
| 2018 FY | 1.46 Billion TWD | -66.87% |
| 2018 Q1 | 4.16 Billion TWD | -5.66% |
| 2018 Q4 | 1.46 Billion TWD | -26.06% |
| 2017 Q3 | 4.15 Billion TWD | -3.88% |
| 2017 Q4 | 4.41 Billion TWD | 6.23% |
| 2017 FY | 4.41 Billion TWD | 62.56% |
| 2017 Q1 | 4.28 Billion TWD | 57.95% |
| 2017 Q2 | 4.32 Billion TWD | 0.79% |
| 2016 Q4 | 2.71 Billion TWD | -34.84% |
| 2016 FY | 2.71 Billion TWD | -34.0% |
| 2016 Q3 | 4.16 Billion TWD | 1.87% |
| 2016 Q2 | 4.08 Billion TWD | -0.23% |
| 2016 Q1 | 4.09 Billion TWD | -0.35% |
| 2015 Q1 | 3.55 Billion TWD | -1.3% |
| 2015 Q2 | 3.52 Billion TWD | -0.75% |
| 2015 Q3 | 4.24 Billion TWD | 20.22% |
| 2015 Q4 | 4.11 Billion TWD | -3.03% |
| 2015 FY | 4.11 Billion TWD | 14.2% |
| 2014 Q1 | 358.21 Million TWD | 0.65% |
| 2014 Q3 | 174.82 Million TWD | -51.51% |
| 2014 Q2 | 360.51 Million TWD | 0.64% |
| 2014 FY | 3.6 Billion TWD | 911.62% |
| 2014 Q4 | 3.6 Billion TWD | 1959.53% |
| 2013 Q2 | 73.1 Million TWD | -8.36% |
| 2013 Q3 | 66.4 Million TWD | -9.17% |
| 2013 Q4 | 355.92 Million TWD | 436.01% |
| 2013 FY | 355.92 Million TWD | 620.27% |
| 2013 Q1 | 79.77 Million TWD | 61.44% |
| 2012 FY | 49.41 Million TWD | 0.0% |
| 2012 Q1 | - TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2012 Q3 | - TWD | 0.0% |
| 2012 Q4 | 49.41 Million TWD | 0.0% |
| 2011 Q2 | 311.74 Million TWD | 0.72% |
| 2011 Q1 | 309.51 Million TWD | 0.72% |
| 2011 FY | - TWD | -100.0% |
| 2011 Q4 | - TWD | -100.0% |
| 2011 Q3 | 313.97 Million TWD | 0.71% |
| 2010 Q4 | 307.29 Million TWD | 0.0% |
| 2010 FY | 307.29 Million TWD | 3411.9% |
| 2009 FY | 8.75 Million TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Grape King Bio Ltd | 136.36 Million TWD | -6881.069% |
| Standard Chem & Pharm CO., LTD. | 222.97 Million TWD | -4169.3% |
| Maywufa Company Ltd. | 438.97 Million TWD | -2068.539% |
| ScinoPharm Taiwan, Ltd. | 570.23 Million TWD | -1569.391% |
| LIWANLI Innovation Co., Ltd. | 361 Thousand TWD | -2636849.03% |
| YungShin Global Holding Corporation | 241.99 Million TWD | -3833.696% |
| PhytoHealth Corporation | 17.46 Million TWD | -54421.111% |
| SCI Pharmtech, Inc. | 845.52 Million TWD | -1025.851% |
| Formosa Laboratories, Inc. | 2.03 Billion TWD | -367.118% |
| PharmaEssentia Corporation | 954.99 Million TWD | -896.796% |
| Bora Pharmaceuticals Co., LTD. | 3.48 Billion TWD | -173.0% |